IRVINE, Calif.--(BUSINESS WIRE)--Sept. 5, 2006--Clinical trial results from Cortex Pharmaceuticals, Inc.'s (AMEX: COR) lead AMPAKINE(R) compound, CX717, were accepted for presentation at the annual meeting of the American Academy of Child and Adolescent Psychiatry in San Diego on October 27, 2006. Dr. Lenard Adler, Director for the Adult ADHD Program, and Associate Professor of Psychiatry and Neurology at New York University School of Medicine and lead study investigator, will present the positive findings from the Phase IIa clinical trial of CX717 in adults with attention deficit / hyperactivity disorder (ADHD). As previously announced, the primary finding from the study was that, by repeated measures analysis, CX717 at a dose of 800 mg twice a day (n = 23) was significantly more effective than placebo on the total ADHD Rating Scale (p=0.0024) and on both the hyperactivity (p=0.0168) and inattentiveness (p=0.0273) subscales. The 200 mg twice a day dose (n=28) did not separate from placebo. Sleep disturbances and headaches were the most frequently reported adverse events. No significant safety concerns or changes in cardiovascular parameters were observed with either dose of CX717.
